A Phase 1b study of the OxPhos inhibitor ME-344 with bevacizumab in refractory metastatic colorectal cancer
Patrick M. Boland(Roswell Park Comprehensive Cancer Center), Michael J. Pishvaian(The University of Texas MD Anderson Cancer Center), Richard Ghalie(MEI Pharma (United States)), Sandra E. Wiley(MEI Pharma (United States)), Vaia Florou(University of Utah), Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center), Deirdre Jill Cohen(Icahn School of Medicine at Mount Sinai), Kristen K. Ciombor(Vanderbilt University Medical Center), Mike Cusnir(Mount Sinai Medical Center), Min Tang(Ningbo No. 2 Hospital), Jessie Yanxiang Guo(Rutgers, The State University of New Jersey), Prabhu Rajagopalan(Mountain Lakes High School)
Cited by 4
Related Papers
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
|The Lancet Oncology|2017|2.8k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis
|Genes & Development|2011|1.3k
Rectal Cancer, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|998